Med­Co builds its case for star cho­les­terol RNAi ther­a­py with two new pos­i­tive piv­otal stud­ies

Weeks af­ter un­veil­ing late-stage da­ta that gave its cho­les­terol fight­er a clean safe­ty pro­file, The Med­i­cines Com­pa­ny is back with two more Phase III datasets …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER